Marshall Wace North America’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Marshall Wace North America’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13,003	Closed	-$316K	–	1535
2020 Q2	$316K	Buy	+13,003	New	+$215K	﹤0.01%	998
2020 Q1	–	Sell	-13,793	Closed	-$365K	–	1665
2019 Q4	$365K	Buy	+13,793	New	+$323K	﹤0.01%	872
2019 Q3	–	Sell	-16,393	Closed	-$503K	–	1597
2019 Q2	$503K	Buy	16,393 +9,773	+148%	+$206K	﹤0.01%	890
2019 Q1	$110K	Sell	6,620 -82,289	-93%	-$1.56M	﹤0.01%	1098
2018 Q4	$1.7M	Buy	88,909 +83,055	+1,419%	+$3.11M	0.02%	461
2018 Q3	$306K	Buy	+5,854	New	+$319K	﹤0.01%	785

Other funds holding GTHX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Marshall Wace North America's GTHX Position: Q3 2020 in Review

Marshall Wace North America sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2020, closing a stake of 13,003 shares — an estimated $316K sold.

Marshall Wace North America first reported a position in GTHX in Q3 2018 and held it in 6 quarters. The position peaked at $1.7M in Q4 2018. 118 funds tracked by Wall St. Rank hold GTHX as of Q3 2020.

Marshall Wace North America reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Marshall Wace North America sold 13,003 G1 Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $316K.
Marshall Wace North America first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 6 quarters.
Marshall Wace North America's G1 Therapeutics, Inc. Common Stock position peaked at $1.7M in Q4 2018.
118 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.